Previous study has confirmed that the mutation and loss of function of PBRM1 promote immune cell infiltration, which may affect the efficacy of immunotherapy for RCC.[33] Thus, we aimed to evaluate the effects and regulatory mechanisms of wild‐type PBRM1 on immunotherapy of RCC. This evidence concerns the gene PBRM1 and renal cell adenocarcinoma.